How to buy Anika Therapeutics stock (ANIK)

Anika Therapeutics is a drug manufacturers - specialty & generic business based in the US. Anika Therapeutics shares (ANIK) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $16.33 – the same closing value as a week prior. Anika Therapeutics employs 357 staff and has a trailing 12-month revenue of around $164.2 million.

Our top picks for where to buy Anika Therapeutics stock

Buy Anika Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Anika Therapeutics stock price (NASDAQ: ANIK)

Use our graph to track the performance of ANIK stocks over time.

Anika Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-25.

Latest market close	$16.33
52-week range	$15.83 - $29.12
50-day moving average more info button	$18.93
200-day moving average more info button	$24.09
Wall St. target price	$26.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-6.64

Is it a good time to buy Anika Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Anika Therapeutics price performance over time

Historical closes compared with the close of $16.33 from 2024-12-24

1 week (2024-12-19)	16.33
1 month (2024-11-26)	-7.84%
3 months (2024-09-26)	-33.70%
6 months (2024-06-26)	-36.34%

1 year (2023-12-26)	-28.38%
2 years (2022-12-23)	-41.45%
3 years (2021-12-23)	37.99
5 years (2019-12-26)	52.99

Is Anika Therapeutics stock undervalued or overvalued?

Valuing Anika Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Anika Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Anika Therapeutics's PEG ratio

Anika Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.4745. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Anika Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Anika Therapeutics financials

Revenue TTM	$164.2 million
Gross profit TTM	$96.8 million
Return on assets TTM	-4.01%
Return on equity TTM	-43.31%
Profit margin	-59.4%
Book value	$12.24
Market Capitalization more info button	$239.2 million

TTM: trailing 12 months

Anika Therapeutics share dividends

We're not expecting Anika Therapeutics to pay a dividend over the next 12 months.

Anika Therapeutics share price volatility

Over the last 12 months, Anika Therapeutics's shares have ranged in value from as little as $15.825 up to $29.115. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anika Therapeutics's is 0.857. This would suggest that Anika Therapeutics's shares are less volatile than average (for this exchange).

Anika Therapeutics overview

Anika Therapeutics, Inc. , a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Frequently asked questions

null
What percentage of Anika Therapeutics is owned by insiders or institutions?
Currently 3.42% of Anika Therapeutics shares are held by insiders and 91.591% by institutions. How many people work for Anika Therapeutics?
Latest data suggests 357 work at Anika Therapeutics. When does the fiscal year end for Anika Therapeutics?
Anika Therapeutics's fiscal year ends in December. Where is Anika Therapeutics based?
Anika Therapeutics's address is: 32 Wiggins Avenue, Bedford, MA, United States, 01730 What is Anika Therapeutics's ISIN number?
Anika Therapeutics's international securities identification number is: US0352551081 What is Anika Therapeutics's CUSIP number?
Anika Therapeutics's Committee on Uniform Securities Identification Procedures number is: 035255108